A MONOCLONAL-ANTIBODY REACTIVE WITH NORMAL AND LEUKEMIC HUMAN MYELOID PROGENITOR CELLS
A MONOCLONAL-ANTIBODY REACTIVE WITH NORMAL AND LEUKEMIC HUMAN MYELOID PROGENITOR CELLS
复制标题
DOI：
10.1016/0145-2126(84)90001-8
复制
发表时间：
1984-01-01
影响因子：
2.7
通讯作者：
SCHLOSSMAN, SF
中科院分区：
文献类型：
--
作者：
GRIFFIN, JD;LINCH, D;SCHLOSSMAN, SF
抗MY9是一种IgG2b鼠源性单抗，用于与未成熟的正常人髓系细胞发生反应。MY9抗原由骨髓中的原始细胞、早幼粒细胞和髓细胞以及外周血中的单核细胞表达。红细胞、淋巴细胞和血小板MY9阴性。所有髓系集落形成细胞(CFU-GM)、部分红系祖细胞(BFU-E)和多能祖细胞(CFU-GEMM)均为MY9阳性。这种抗原在大多数AML和髓系CML-BC患者的白血病细胞中进一步表达。大多数患者的白血病干细胞(白血病集落形成细胞，L-CFCs)也呈MY9阳性。相反，在淋巴细胞性白血病中未检测到MY9。抗MY9抗体可能是一种有价值的造血祖细胞纯化试剂和髓系白血病的诊断试剂。
Anti-MY9 is an IgG2b murine monoclonal antibody selected for reactivity with immature normal human myeloid cells. The MY9 antigen is expressed by blasts, promyelocytes and myelocytes in the bone marrow, and by monocytes in the peripheral blood. Erythrocytes, lymphocytes and platelets are MY9 negative. All myeloid colony-forming cells (CFU-GM), a fraction of erythroid burst-forming cells (BFU-E) and multipotent progenitors (CFU-GEMM) are MY9 positive. This antigen is further expressed by the leukemic cells of a majority of patients with AML and myeloid CML-BC. Leukemic stem cells (leukemic colony-forming cells, L-CFC) from most patients tested were also MY9 positive. In contrast, MY9 was not detected on lymphocytic leukemias. Anti-MY9 may be a valuable reagent for the purification of hematopoietic colony-forming cells and for the diagnosis of myeloid-lineage leukemias.